Comparison of Three-chamber-bag Versus Compounded Bag
This study has been completed.
Sponsor:
B. Braun Melsungen AG
Information provided by (Responsible Party):
B. Braun Melsungen AG
ClinicalTrials.gov Identifier:
NCT01247740
First received: November 23, 2010
Last updated: January 9, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to investigate the efficacy and safety of a convenient 3-chamber-bag containing aminoacids, glucose and lipid emulsion (LCT/MCT 20%) compared to a conventionally compounded monobag for parenteral nutrition.
| Condition | Intervention | Phase |
|---|---|---|
|
Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption |
Drug: NuTRIflex Lipid peri Drug: compounded monobag |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Prospective, Controlled, Randomized, Blinded, Parallel Group Multicentre Study on the Safety and Efficacy of a Convenience Three-chamber Bag for Parenteral Nutrition in Post-operative Patients After Abdominal Surgery Versus a Compounded Monobag |
Resource links provided by NLM:
Further study details as provided by B. Braun Melsungen AG:
Primary Outcome Measures:
- Course of prealbumin (from day 1 to day 7) [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- clinical outcome parameters, haematology, liver function, blood biochemistry and electrolytes, coagulation function [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
| Enrollment: | 240 |
| Study Start Date: | October 2010 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
|
Drug: NuTRIflex Lipid peri
parenteral nutrition
|
|
Active Comparator: 2
compounded monobag including lipids, glucose, amino acids and electrolytes
|
Drug: compounded monobag
parenteral nutrition
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion: •Patients considered for elective open abdominal surgery
- Male and female patients ≥18 and <85 years of age
- Indication for total parenteral nutrition therapy: for 6 consecutive days
- NRS ≥3
- Ability and willingness to give voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the informed consent form approved by the Institutional Review Board (IRB) prior to all evaluations, and to comply with the requirements of the study
Exclusion: Major criteria:
- Body weight < 50 kg or > 70 kg
- Laparoscopic surgery
- Seriously ill patients in need of high energy nutrition support (i. e. > 2100 Kcal/day)
- Hepatic surgery
- Surgery with estimated blood loss >1000ml
- Participation in a clinical study with an investigational drug or an investigational medical device within one month prior to the start of study
- Receiving regular parenteral nutrition within 7 days before the onset of study
- General contraindications for parenteral nutrition (acidosis of various geneses, untreated disorders of electrolyte and fluid balance, hyperhydration, acute pulmonary edema, inadequate cellular oxygen supply)
- General contraindications for infusion therapy such as acute pulmonary oedema, hyperhydration and decompensated cardiac insufficiency, acute stroke
- Known hypersensitivity to egg-, soy-, and peanut proteins or any of the ingredients
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01247740
Locations
| China | |
| Peking Union Medical College Hospital,Department of Gastrointestinal Surgery | |
| Beijing, China | |
Sponsors and Collaborators
B. Braun Melsungen AG
Investigators
| Principal Investigator: | Jianchun Yu, Prof. | Peking Union Medical College Hospital,Department of Gastrointestinal Surgery |
More Information
No publications provided
| Responsible Party: | B. Braun Melsungen AG |
| ClinicalTrials.gov Identifier: | NCT01247740 History of Changes |
| Other Study ID Numbers: | HC-G-H-0805 |
| Study First Received: | November 23, 2010 |
| Last Updated: | January 9, 2012 |
| Health Authority: | China: Food and Drug Administration |
ClinicalTrials.gov processed this record on May 21, 2013